TAR200 for non-muscle invasive bladder cancer, a novel approach | Dr. Rana McKay | Oncology Brothers
338 بار بازدید -
9 ماه پیش
-
In discussion with Dr. Rana
In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay:
- SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG - with TAR-200 mono therapy achieving 77% overall complete response rate
- EV-302 – Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Metastatic Urothelial Cancer, which showed impressive PFS and OS
- PSMAfore – 177Lu-PSMA-617 Versus Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer with impressive responsiveness
#ESMO #PrecisionMedicine #GUCancer #Kidney #Bladder #Prostate #2023 #cancer #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: Twitter: oncbrothers
Contact us at [email protected]
- SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG - with TAR-200 mono therapy achieving 77% overall complete response rate
- EV-302 – Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Metastatic Urothelial Cancer, which showed impressive PFS and OS
- PSMAfore – 177Lu-PSMA-617 Versus Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer with impressive responsiveness
#ESMO #PrecisionMedicine #GUCancer #Kidney #Bladder #Prostate #2023 #cancer #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: Twitter: oncbrothers
Contact us at [email protected]
9 ماه پیش
در تاریخ 1402/08/17 منتشر شده
است.
338
بـار بازدید شده